Project BioShield

Project BioShield Procurement

Administers late-stage medical countermeasure development with United States government procurement pathways for strategic stockpile readiness.

Project BioShield, authorized by the Project BioShield Act of 2004 and funded through the Biomedical Advanced Countermeasure Development Fund, is the U.S. government's procurement mechanism for late-stage medical countermeasures (MCMs) against CBRN threats. BARDA administers Project BioShield contracts on behalf of the U.S. Department of Health and Human Services, using the authority to acquire MCMs for the Strategic National Stockpile (SNS) before they have received full FDA approval. The program funds the final advanced-development push to FDA approval or Emergency Use Authorization as well as the manufacture and delivery of finished doses into the SNS.

Project BioShield contracts are typically multi-year, ranging from $10 million to $500 million, with an estimated median of $80 million and an estimated annual pool of roughly $800 million. The instrument is structured as a procurement contract with embedded advanced-development funding: awardees commit to manufacturing and delivering specified quantities at agreed prices to the SNS, which recovers the government's investment upon delivery. Many contracts are structured as Other Transaction Authorities (OTAs) rather than FAR contracts, providing flexibility on intellectual property and cost-accounting requirements. Universities are generally ineligible; the program targets for-profit companies and research organizations with manufacturing capability. Minimum TRL at entry is typically 7, targeting candidates through TRL 9.

Most Project BioShield awardees have completed prior advanced development through BARDA's BAA, DoD's Chemical and Biological Defense Program, NIH NIAID, or private investment before competing for a stockpile contract. U.S.-based manufacturing is required for stockpile-destined components. Foreign-owned firms may compete but face additional scrutiny. Strong positioning requires demonstrated GMP manufacturing readiness, a clear FDA regulatory pathway, and evidence that the MCM addresses a current SNS gap identified in BARDA's public acquisition strategies.